vimarsana.com

Page 204 - ஃப்ரெட் ஹட்சின்சன் புற்றுநோய் ஆராய்ச்சி மையம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Around 4,400 adverse events reported in US after receiving Pfizer-BioNTech vaccine

Covid-19 vaccines: Single jab of current two-dose regimens may offer greater population benefit

First case of new COVID-19 variant now confirmed in Texas

First case of new COVID-19 variant now confirmed in Texas First case of new COVID-19 variant now confirmed in Texas By ABC13 Staff The COVID19 variant B.1.1.7 has struck an area man. Andriy Onufriyenko/Getty Images Harris County Public Health has confirmed the first case of the COVID19 variant B.1.1.7, the same variant discovered in the UK. This the first known case in the state of Texas. The patient has been identified as a man between ages 30 and 40 in southwest Harris County.  His condition is described as stable, and the man is quarantining in isolation. Authorities say he has no travel history and are reaching out to anyone the man has come into contact with.

PI3K/AKT/mTOR Inhibitors for Prostate Cancer – Finally Hints of a Breakthrough

PI3K/AKT/mTOR Inhibitors for Prostate Cancer – Finally Hints of a Breakthrough Published 05 January 2021 Activation of the phosphatidylinositol 3-kinase (PI3K)/Akt/mammalian target of rapamycin (mTOR) pathway has been strongly linked with prostate cancer progression and metastatic potential. 1 Loss of the inhibitory phosphatase, PTEN, leading to hyperactivation of PI3K/AKT/mTOR oncogenic signaling, occurs in 40-50% of metastatic castration-resistant prostate cancer. 1,2 Not surprising is the fact that PTEN loss in patients with metastatic castration-resistant prostate cancer is associated with a worse prognosis and less benefit from androgen receptor (AR) blockade. 3 Likewise, PTEN loss and subsequent Akt activation confer radiation

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.